Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 9

Results For "Gastrointestinal"

88 News Found

Lupin launch a generic version of pain reliever for osteoarthritis in the US
Drug Approval | September 15, 2021

Lupin launch a generic version of pain reliever for osteoarthritis in the US

Ibuprofen and Famotidine tablets (Duexise) had estimated annual sales of US $ 765 million in the US as if July 21


Merck’s KEYTRUDA receives China approval for Esophageal cancer
Drug Approval | September 09, 2021

Merck’s KEYTRUDA receives China approval for Esophageal cancer

The medicine is now approved for eight indications across five different types of cancer in China.


Indian Pharmaceutical Market grew by 17.7 per cent in August
News | September 07, 2021

Indian Pharmaceutical Market grew by 17.7 per cent in August

Ind-Ra expects IPM revenue to grow over 12% YoY in FY22


Roche withdraws the US accelerated approval for Tecentriq
Drug Approval | August 28, 2021

Roche withdraws the US accelerated approval for Tecentriq

Roche is notifying healthcare professionals and patients in the US about this withdrawal. Patients being treated with Tecentriq for PD-L1-positive mTNBC should discuss their care with their healthcare provider


RedHill Biopharma's Opaganib demonstrates strong inhibition of COVID-19 Delta variant
Drug Approval | August 26, 2021

RedHill Biopharma's Opaganib demonstrates strong inhibition of COVID-19 Delta variant

Opaganib, a leading novel small molecule investigational oral pill in development for Covid-19, is a unique host targeted, dual antiviral and anti-inflammatory drug that acts on the cause and effect of the disease


Dr. Reddy's Sputnik V India price is Rs. 995.40
News | May 15, 2021

Dr. Reddy's Sputnik V India price is Rs. 995.40

The company is working closely with its six manufacturing partners in India


Hester launches herbal veterinary product range
News | April 26, 2021

Hester launches herbal veterinary product range

In animal health, the products will be mainly targeting mastitis and production disorders, gastrointestinal tract diseases, reproductive disorders, ectoparasites, and skin injuries


Vivimed Labs receives products approvals from Uzbekistan
News | March 09, 2021

Vivimed Labs receives products approvals from Uzbekistan

Vivimed strategy is to increase its share of Branded products in CIS Markets.